Gene Therapy Cures Stalled by Financing Gap
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Gene therapies cure diseases like sickle cell with a single $2 million+ treatment, concentrating decades of medical value into one intervention
- Centers for Medicare and Medicaid Services launched the Cell and Gene Therapy Access Model to help state Medicaid programs negotiate outcomes-based payments and pool risk
- State Medicaid programs and insurers face difficulty absorbing $2 million upfront costs due to annual budget constraints, limiting coverage and slowing approvals
- Manufacturers and treatment centers confront constrained clinical capacity, as gene therapies require specialized teams and facilities similar to organ transplants
Why it matters: Patients with curable conditions lose access because payers can't finance upfront costs, while manufacturers face uncertainty in scaling production—despite the long-term savings these cures promise. The bottleneck isn't science, but payment infrastructure.
Ask SkimNews
